Literature DB >> 3362419

Dextromethorphan protects against cerebral infarction in a rat model of hypoxia-ischemia.

D A Prince1, H R Feeser.   

Abstract

We assessed the cerebral protective effects of the noncompetitive N-methyl-D-aspartate antagonist dextromethorphan (DM; 10-35 mg/kg i.p.) in 8-day-old rats that were subjected to brain hypoxia-ischemia by tying one carotid artery and placing them in 8% O2-92% N2 for 2 h. Light microscopic examination of brains perfused one week after the insult revealed that all control animals developed a frank infarction with cavitation and brain shrinkage in the middle cerebral artery territory. There was a highly significant decrease in the incidence of frank infarction in DM-pre-treated pups vs saline-treated littermates, although there was no clear relationship between drug dose and the degree of brain protection. DM and its active metabolite dextrorphan may prove to be clinically useful in protecting against hypoxia-ischemia.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3362419     DOI: 10.1016/0304-3940(88)90581-2

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  8 in total

1.  Excitatory amino acid neurotoxicity--a broader horizon for cerebral protection?

Authors:  R C Tasker
Journal:  Arch Dis Child       Date:  1992-11       Impact factor: 3.791

2.  Dextromethorphan in nonketotic hyperglycinaemia: metabolic variation confounds the dose-response relationship.

Authors:  G L Arnold; M L Griebel; J L Valentine; D M Koroma; G L Kearns
Journal:  J Inherit Metab Dis       Date:  1997-03       Impact factor: 4.982

3.  Ischemia-induced changes in the electrical activity of the hippocampus.

Authors:  G Buzsàki; T F Freund; F Bayardo; P Somogyi
Journal:  Exp Brain Res       Date:  1989       Impact factor: 1.972

4.  Blockade by ifenprodil of high voltage-activated Ca2+ channels in rat and mouse cultured hippocampal pyramidal neurones: comparison with N-methyl-D-aspartate receptor antagonist actions.

Authors:  J Church; E J Fletcher; K Baxter; J F MacDonald
Journal:  Br J Pharmacol       Date:  1994-10       Impact factor: 8.739

Review 5.  Dextromethorphan. An overview of safety issues.

Authors:  J L Bem; R Peck
Journal:  Drug Saf       Date:  1992 May-Jun       Impact factor: 5.606

Review 6.  Excitatory amino acid antagonists and their potential for the treatment of ischaemic brain damage in man.

Authors:  J McCulloch
Journal:  Br J Clin Pharmacol       Date:  1992-08       Impact factor: 4.335

7.  Effects of dextromethorphan and oxycodone on treatment of neuropathic pain in mice.

Authors:  Pao-Pao Yang; Geng-Chang Yeh; Eagle Yi-Kung Huang; Ping-Yee Law; Horace H Loh; Pao-Luh Tao
Journal:  J Biomed Sci       Date:  2015-09-22       Impact factor: 8.410

8.  Low-dose dextromethorphan, a NADPH oxidase inhibitor, reduces blood pressure and enhances vascular protection in experimental hypertension.

Authors:  Tao-Cheng Wu; Chih-Yu Chao; Shing-Jong Lin; Jaw-Wen Chen
Journal:  PLoS One       Date:  2012-09-25       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.